Global Health News: Vaccine Stocks, Market Moves, and Policy Shifts

This health news summary discusses the mpox vaccine stockpiles in rich nations, Moderna's financial forecast, Morocco's first mpox case, WHO's approval of Bavarian Nordic's vaccine, Africa CDC’s funding goals, China’s birth rate measures, Neurocrine's halted drug development, GSK’s mRNA flu vaccine trials, Roche's obesity pill concerns, and North Dakota's abortion ban overturn.

Global health dynamics are shifting as rich nations hold millions of mpox vaccine doses amidst Africa's outbreak. Meanwhile, Moderna's shares drop with a grim sales forecast, and Morocco reports its first mpox case. In a significant development, WHO approves Bavarian Nordic's vaccine to curb the virus spread.

Africa CDC expresses confidence in raising $600 million to combat the crisis. Concurrently, China's health commission advocates for marriage and childbirth at appropriate ages to address the declining birth rate. On the drug development front, Neurocrine halts its schizophrenia drug program, while GSK advances its mRNA flu vaccine to late-stage trials.

Roche faces setbacks with its obesity pill due to side effects, and a North Dakota judge overturns the state's strict abortion ban, upholding women's rights. These events mark significant shifts in the global health landscape.

(With inputs from agencies.)